HMGA1 and acute myeloid leukemia: In addition, HMGA1 depletion seems to enhance responses to ruxolitinib in murine MF models, and to prolong survival in murine models of JAK2V617F AML, showing HMGA1 as a promising therapeutic target to treat or prevent disease progression [72].